Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …

Aptamers are short, single-stranded DNA, RNA, or synthetic XNA molecules that can be
developed with high affinity and specificity to interact with any desired targets. They have …

Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that plays an
oncogenic role in breast, gastric and other solid tumors. However, anti-HER2 therapies are …

The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage
innate immune effectors through interactions mediated by their fragment crystallizable (Fc) …

In addition to being a component of innate immunity and an ancient defense mechanism
against invading pathogens, complement activation also participates in the adaptive …

CD 38 is a multifunctional cell surface protein that has receptor as well as enzyme functions.
The protein is generally expressed at low levels on various hematological and solid tissues …

Antibodies are important therapeutic agents for cancer. Recently, it has become clear that
antibodies possess several clinically relevant mechanisms of action. Many clinically useful …

The development of therapeutic antibodies has evolved over the past decade into a
mainstay of therapeutic options for patients with autoimmune and inflammatory diseases …

Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies. Despite its
undeniable therapeutic value, we still do not fully understand the mechanisms of action …

Exceptional advances in molecular biology and genetic research have expedited cancer
drug development tremendously. The declared paradigm is the development …